ALNYLAM PHARMACEUTICALS, INC. - 8-K Filing

Alnylam Pharmaceuticals reported Q2 2026 TTR net product revenues of $1.03B, up 89% YoY (Items: 2.02 Results of Operations and Financial ConditionOn July 30, 2026, Alnylam Pharmaceuticals, Inc, 9.01 Financial Statements and Exhibits (d) ExhibitsThe following exhibit relating to Item 2)

SEC EDGAR · July 30, 2026, 12:07 UTC

Tickers: $ALNY

Read the full article at SEC EDGAR

More Regulatory news

Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC
Beyond Air, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:17 UTC